Form D · Pharmaceuticals

HLS Therapeutics Inc.

Caledon, A6 · CIK 0001648315

Offering snapshot reported Aug 26, 2015 · SEC filing

Reported sold
$30M
Offering amount: $30M
Investors reported
4
Form D · investor count
Minimum accepted
$2.78M
Reported outside-investor minimum
First sale
Aug 11, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 26, 2015Initial$30,000,000No comparison4SEC filing
Jul 17, 2015Initial$112,787,710No comparison22SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$1.8M
Finders' fees
$0
Form D file number
021-246478
In addition to the advisory fees disclosed above, advisory warrants to purchase 180,000 common shares at an exercise price of US$10.00 per common share through August 11, 2017.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
GMP Securities, LLC41025

Source: Form D, filed Aug 26, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Chris Fibiger Executive
Gilbert Godin Director, Executive
Gregory D Gubitz Director, Executive, Promoter
Joseph Mac Lean Director, Executive
Bill Wells Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
17474 Humber Station Road
Caledon, A6, L7E 0Z2